FIELD: pharmacology.
SUBSTANCE: invention relates to compounds of formula (I)
.
New compounds and their crystalline forms that inhibit Ax1 and are useful for treatment of diseases caused by Ax1 hyperfunction, diseases associated with Ax1 hyperfunction, and/or diseases accompanied by Ax1 hyperfunction, such as hyperoproliferative disease.
EFFECT: means have increased effectiveness.
37 cl, 16 tbl, 107 ex, 16 dwg
Title | Year | Author | Number |
---|---|---|---|
PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | 2015 |
|
RU2707953C2 |
TETRAHYDROPYRIDINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | 2017 |
|
RU2722594C1 |
SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | 2014 |
|
RU2671212C2 |
TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNELS INHIBITOR | 2013 |
|
RU2645158C2 |
SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
NOVEL PYRIDINE DERIVATIVE AND DERIVATIVE OF PYRIMIDINE (3) | 2006 |
|
RU2362771C1 |
PYRIDINONE AND PYRIDAZINONE DERIVATIVES | 2012 |
|
RU2632915C2 |
CONDENSED AMINOHYDROTHIAZINE DERIVATIVE | 2009 |
|
RU2476431C2 |
IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | 2013 |
|
RU2635917C2 |
5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | 2014 |
|
RU2673810C1 |
Authors
Dates
2017-10-11—Published
2013-01-30—Filed